Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Stratford, Connecticut 06615


Purpose:

We are testing to see if Galantamine, a learning enhancing medication, will help methadone maintained cocaine abusers with their learning and memory specific to CBT using an innovative CBT computer program.


Study summary:

We are proposing a randomized double blind clinical trial of galantamine and our innovative computer-assisted version of CBT, alone and in combination, to improve treatment outcome and cognitive functioning among cocaine users. The proposed study will be the first to evaluate a cognitive enhancing medication as a means of enhancing the effects of an extremely promising empirically validated behavioral therapy for addiction, and hence bridge cognitive neuroscience and behavioral therapies development. The aim is to conduct a 12 week randomized placebo controlled trial, using a 2x2 factorial model, that will evaluate the efficacy of adding computer assisted training in CBT ("CBT4CBT") and galantamine to standard treatment for 160 cocaine abusing or dependent methadone-maintained individuals. Participants will be randomized to (1) standard treatment (TAU) plus placebo, (2) TAU plus galantamine, (3) TAU plus CBT4CBT plus placebo, or (4) TAU plus CBT4CBT plus galantamine.


Criteria:

Inclusion Criteria: - Males and females between ages of 18 and 50 - Enrolled in RNP methadone program and stable on methadone for at least 3 weeks - Current cocaine abuse or dependence according to DSM-IV criteria - No current medical problems and normal ECG - If female, not currently pregnant or breast feeding and using reliable birth control - Fluent in English and have at least a 6th grade reading level - Can commit to 12 weeks of treatment and are willing to be randomized Exclusion Criteria: - Current major psychiatric illness including mood, psychotic or anxiety disorder - History of major medical illnesses including asthma, chronic obstructive lung disease, gastrointestinal ulcer, hepatic or renal impairment, cardiac rhythm disturbances - Use of medications including beta blockers and NASAIDs - Known allergy to Galantamine


NCT ID:

NCT00809835


Primary Contact:

Principal Investigator
Kathleen M Carroll, Ph.D.
Yale University


Backup Contact:

N/A


Location Contact:

Stratford, Connecticut 06615
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.